{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T18:08:47Z","timestamp":1792174127397,"version":"4.4.0"},"reference-count":54,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100007614","name":"Jouf University","doi-asserted-by":"publisher","award":["DGSSR-2025-02-01151"],"award-info":[{"award-number":["DGSSR-2025-02-01151"]}],"id":[{"id":"10.13039\/501100007614","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Chromatography B"],"published-print":{"date-parts":[[2026,3]]},"DOI":"10.1016\/j.jchromb.2026.124927","type":"journal-article","created":{"date-parts":[[2026,1,19]],"date-time":"2026-01-19T15:59:37Z","timestamp":1768838377000},"page":"124927","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"special_numbering":"C","title":["High-sensitivity dual analysis of Baricitinib and remdesivir in serum and urine using HPLC-fluorescence and LC-MS approaches in COVID-19 therapy"],"prefix":"10.1016","volume":"1272","author":[{"given":"Hazim M.","family":"Ali","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lateefa A.","family":"Al-Khateeb","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohammed M.","family":"Ghoneim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maha M.","family":"Abdelrahman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ismail M.","family":"Ahmed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohammed","family":"Gamal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"6","key":"10.1016\/j.jchromb.2026.124927_bb0005","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1080\/10408363.2020.1783198","article-title":"The COVID-19 pandemic","volume":"57","author":"Ciotti","year":"2020","journal-title":"Crit. Rev. Clin. Lab. Sci."},{"key":"10.1016\/j.jchromb.2026.124927_bb0010","doi-asserted-by":"crossref","DOI":"10.1016\/j.bios.2020.112454","article-title":"Diagnostics for SARS-CoV-2 detection: a comprehensive review of the FDA-EUA COVID-19 testing landscape","volume":"165","author":"Ravi","year":"2020","journal-title":"Biosens. Bioelectron."},{"issue":"6","key":"10.1016\/j.jchromb.2026.124927_bb0015","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1016\/j.trac.2008.05.003","article-title":"Green analytical chemistry","volume":"27","author":"Armenta","year":"2008","journal-title":"TrAC Trends Anal. Chem."},{"key":"10.1016\/j.jchromb.2026.124927_bb0020","doi-asserted-by":"crossref","DOI":"10.1016\/j.teac.2023.e00202","article-title":"How environmentally friendly is the analytical process? A paradigm overview of ten greenness assessment metric approaches for analytical methods","volume":"38","author":"Imam","year":"2023","journal-title":"Trends Environ. Anal. Chem."},{"issue":"8","key":"10.1016\/j.jchromb.2026.124927_bb0025","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1002\/phar.2438","article-title":"Baricitinib: a review of pharmacology, safety, and emerging clinical experience in COVID-19","volume":"40","author":"Jorgensen","year":"2020","journal-title":"Pharmacother. J. Hum. Pharmacol. Drug Ther."},{"issue":"9","key":"10.1016\/j.jchromb.2026.124927_bb0030","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1177\/1060028019839650","article-title":"Baricitinib: the second FDA-approved JAK inhibitor for the treatment of rheumatoid arthritis","volume":"53","author":"Mogul","year":"2019","journal-title":"Ann. Pharmacother."},{"issue":"5","key":"10.1016\/j.jchromb.2026.124927_bb0035","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1021\/acscentsci.0c00489","article-title":"Remdesivir: a review of its discovery and development leading to emergency use authorization for treatment of COVID-19","volume":"6","author":"Eastman","year":"2020","journal-title":"ACS Cent. Sci."},{"issue":"11","key":"10.1016\/j.jchromb.2026.124927_bb0040","doi-asserted-by":"crossref","first-page":"1048","DOI":"10.1001\/jama.2020.16349","article-title":"Effect of remdesivir vs standard care on clinical status at 11 days in patients with moderate COVID-19: a randomized clinical trial","volume":"324","author":"Spinner","year":"2020","journal-title":"Jama"},{"issue":"9","key":"10.1016\/j.jchromb.2026.124927_bb0045","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1056\/NEJMoa2031994","article-title":"Baricitinib plus remdesivir for hospitalized adults with Covid-19","volume":"384","author":"Kalil","year":"2021","journal-title":"N. Engl. J. Med."},{"issue":"6","key":"10.1016\/j.jchromb.2026.124927_bb0050","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1016\/j.resinv.2021.07.004","article-title":"Clinical impact of combination therapy with baricitinib, remdesivir, and dexamethasone in patients with severe COVID-19","volume":"59","author":"Izumo","year":"2021","journal-title":"Respir. Investig."},{"key":"10.1016\/j.jchromb.2026.124927_bb0055","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1007\/s00210-021-02169-0","article-title":"Association and pharmacological synergism of the triple drug therapy baricitinib\/remdesivir\/rhACE2 for the management of COVID-19 infection","volume":"395","author":"Vitiello","year":"2022","journal-title":"Naunyn Schmiedebergs Arch. Pharmacol."},{"issue":"1","key":"10.1016\/j.jchromb.2026.124927_bb0060","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1007\/s42399-022-01121-4","article-title":"Efficacy of combination therapy with the JAK inhibitor baricitinib in the treatment of COVID-19","volume":"4","author":"Thoms","year":"2022","journal-title":"SN Compr. Clin. Med."},{"key":"10.1016\/j.jchromb.2026.124927_bb0065","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.830990","article-title":"Remdesivir and its combination with repurposed drugs as COVID-19 therapeutics","volume":"13","author":"Chatterjee","year":"2022","journal-title":"Front. Immunol."},{"key":"10.1016\/j.jchromb.2026.124927_bb0070","author":"FDA"},{"key":"10.1016\/j.jchromb.2026.124927_bb0075","first-page":"1","article-title":"Perspectives of association Baricitinib\/remdesivir for adults with Covid-19 infection","author":"Vitiello","year":"2022","journal-title":"Mol. Biol. Rep."},{"issue":"2","key":"10.1016\/j.jchromb.2026.124927_bb0080","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1016\/j.pharma.2022.09.001","article-title":"Validated stability indicating chromatographic method for determination of baricitinib and its degradation products in their tablet dosage form: implementation to content uniformity and in vitro dissolution studies","volume":"81","author":"Mohamed","year":"2023","journal-title":"Ann. Pharm. Fr."},{"key":"10.1016\/j.jchromb.2026.124927_bb0085","doi-asserted-by":"crossref","DOI":"10.1016\/j.jchromb.2023.123917","article-title":"Development and validation of a multiplex HPLC-MS\/MS assay for the monitoring of JAK inhibitors in patient plasma","volume":"1230","author":"Tachet","year":"2023","journal-title":"J. Chromatogr. B"},{"issue":"2","key":"10.1016\/j.jchromb.2026.124927_bb0090","doi-asserted-by":"crossref","first-page":"347","DOI":"10.3797\/scipharm.1510-08","article-title":"Simultaneous quantification of baricitinib and methotrexate in rat plasma by LC-MS\/MS: application to a pharmacokinetic study","volume":"84","author":"Veeraraghavan","year":"2016","journal-title":"Sci. Pharm."},{"issue":"7","key":"10.1016\/j.jchromb.2026.124927_bb0095","doi-asserted-by":"crossref","first-page":"1600","DOI":"10.3390\/molecules25071600","article-title":"A Hydrophilic Interaction Liquid Chromatography\u2013Tandem Mass Spectrometry Quantitative Method for Determination of Baricitinib in Plasma, and Its Application in a Pharmacokinetic Study in Rats","volume":"25","author":"Ezzeldin","year":"2020","journal-title":"Molecules"},{"issue":"10","key":"10.1016\/j.jchromb.2026.124927_bb0100","doi-asserted-by":"crossref","first-page":"9583","DOI":"10.1021\/acsomega.3c00100","article-title":"Identification, synthesis, and characterization of novel Baricitinib impurities","volume":"8","author":"Vaddamanu","year":"2023","journal-title":"ACS Omega"},{"key":"10.1016\/j.jchromb.2026.124927_bb0105","first-page":"10","article-title":"A novel LC-MS\/MS method for therapeutic drug monitoring of Baricitinib in plasma of Pediatric patients","author":"Cafaro","year":"2022","journal-title":"Ther. Drug Monit."},{"issue":"3","key":"10.1016\/j.jchromb.2026.124927_bb0110","doi-asserted-by":"crossref","DOI":"10.31788\/RJC.2023.1638344","article-title":"Development And Validation Of Stability Indicating Rp-Hplc Method For The Determination Of Baricitinib And Its Related Drug Substances","volume":"16","author":"Gannamani","year":"2023","journal-title":"Rasayan J. Chem."},{"issue":"23","key":"10.1016\/j.jchromb.2026.124927_bb0115","doi-asserted-by":"crossref","first-page":"5811","DOI":"10.1007\/s00216-021-03561-8","article-title":"Quantitative HPLC-MS\/MS determination of Nuc, the active metabolite of remdesivir, and its pharmacokinetics in rat","volume":"413","author":"Du","year":"2021","journal-title":"Anal. Bioanal. Chem."},{"issue":"12","key":"10.1016\/j.jchromb.2026.124927_bb0120","doi-asserted-by":"crossref","first-page":"243","DOI":"10.3390\/separations8120243","article-title":"Green stability indicating organic solvent-free HPLC determination of remdesivir in substances and pharmaceutical dosage forms","volume":"8","author":"Ibrahim","year":"2021","journal-title":"Separations"},{"key":"10.1016\/j.jchromb.2026.124927_bb0125","doi-asserted-by":"crossref","DOI":"10.1016\/j.jchromb.2021.122641","article-title":"Development and validation of a simple, selective, and sensitive LC-MS\/MS assay for the quantification of remdesivir in human plasma","volume":"1171","author":"Nguyen","year":"2021","journal-title":"J. Chromatogr. B"},{"issue":"2","key":"10.1016\/j.jchromb.2026.124927_bb0130","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1093\/chromsci\/bmab042","article-title":"A novel liquid chromatographic method for the quantitative determination of degradation products in remdesivir injectable drug product","volume":"60","author":"Reddy","year":"2022","journal-title":"J. Chromatogr. Sci."},{"issue":"2","key":"10.1016\/j.jchromb.2026.124927_bb0135","article-title":"Analytical method development and validation of Remdesivir in bulk and pharmaceutical dosage forms using reverse-phase-high performance liquid chromatography","volume":"1","author":"Raasi","year":"2021","journal-title":"BR Nahata Smriti Sansthan Int. J. Phramaceutical Sci. Clin. Res."},{"issue":"1","key":"10.1016\/j.jchromb.2026.124927_bb0140","article-title":"Development, validation and forced degradation studies of green liquid chromatographic method for determination of remdesivir in bulk drug and pharmaceutical formulation","volume":"36","author":"Samad","year":"2023","journal-title":"Pak. J. Pharm. Sci."},{"issue":"7","key":"10.1016\/j.jchromb.2026.124927_bb0145","doi-asserted-by":"crossref","DOI":"10.1002\/bmc.5380","article-title":"Development and validation of an LC\u2013MS\/MS method for simultaneous determination of remdesivir and its hydrolyzed metabolite and nucleoside, and its application in a pharmacokinetic study of normal and diabetic nephropathy mice","volume":"36","author":"Yuan","year":"2022","journal-title":"Biomed. Chromatogr."},{"key":"10.1016\/j.jchromb.2026.124927_bb0150","doi-asserted-by":"crossref","DOI":"10.1016\/j.microc.2022.107580","article-title":"Rapid and ecofriendly UPLC quantification of remdesivir, favipiravir and dexamethasone for accurate therapeutic drug monitoring in Covid-19 patient\u2019s plasma","volume":"179","author":"Emam","year":"2022","journal-title":"Microchem. J."},{"key":"10.1016\/j.jchromb.2026.124927_bb0155","doi-asserted-by":"crossref","DOI":"10.1016\/j.chroma.2023.464468","article-title":"Determination of remdesivir in human plasma using (deep eutectic solvent-ionic liquid) ferrofluid microextraction combined with liquid chromatography","volume":"1712","author":"Morovati","year":"2023","journal-title":"J. Chromatogr. A"},{"key":"10.1016\/j.jchromb.2026.124927_bb0160","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1016\/j.procbio.2020.12.014","article-title":"Rapid determination of remdesivir (SARS-CoV-2 drug) in human plasma for therapeutic drug monitoring in COVID-19-patients","volume":"102","author":"Pasupuleti","year":"2021","journal-title":"Process Biochem."},{"issue":"7","key":"10.1016\/j.jchromb.2026.124927_bb0165","doi-asserted-by":"crossref","first-page":"1772","DOI":"10.1093\/jac\/dkaa152","article-title":"Development and validation of a UHPLC-MS\/MS method for quantification of the prodrug remdesivir and its metabolite GS-441524: a tool for clinical pharmacokinetics of SARS-CoV-2\/COVID-19 and Ebola virus disease","volume":"75","author":"Avataneo","year":"2020","journal-title":"J. Antimicrob. Chemother."},{"key":"10.1016\/j.jchromb.2026.124927_bb0170","doi-asserted-by":"crossref","DOI":"10.1016\/j.ab.2021.114118","article-title":"Validation of LC-MS\/MS methods for determination of remdesivir and its metabolites GS-441524 and GS-704277 in acidified human plasma and their application in COVID-19 related clinical studies","volume":"617","author":"Xiao","year":"2021","journal-title":"Anal. Biochem."},{"issue":"1","key":"10.1016\/j.jchromb.2026.124927_bb0175","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1080\/16583655.2021.1991737","article-title":"A comparative study of HPLC and UV spectrophotometric methods for remdesivir quantification in pharmaceutical formulations","volume":"15","author":"Bulduk","year":"2021","journal-title":"J. Taibah Univ. Sci."},{"issue":"9","key":"10.1016\/j.jchromb.2026.124927_bb0180","doi-asserted-by":"crossref","first-page":"1461","DOI":"10.1515\/cclm-2020-0612","article-title":"Quantification of plasma remdesivir and its metabolite GS-441524 using liquid chromatography coupled to tandem mass spectrometry. Application to a Covid-19 treated patient","volume":"58","author":"Alvarez","year":"2020","journal-title":"Clin. Chem. Lab. Med."},{"issue":"16","key":"10.1016\/j.jchromb.2026.124927_bb0185","doi-asserted-by":"crossref","first-page":"7217","DOI":"10.1039\/D1NJ00160D","article-title":"Identification and characterization of degradation products of remdesivir using liquid chromatography\/mass spectrometry","volume":"45","author":"Dadinaboyina","year":"2021","journal-title":"New J. Chem."},{"key":"10.1016\/j.jchromb.2026.124927_bb0190","doi-asserted-by":"crossref","DOI":"10.1016\/j.jpba.2021.113935","article-title":"Simultaneous quantification of seven repurposed COVID-19 drugs remdesivir (plus metabolite GS-441524), chloroquine, hydroxychloroquine, lopinavir, ritonavir, favipiravir and azithromycin by a two-dimensional isotope dilution LC\u2013MS\/MS method in human serum","volume":"196","author":"Habler","year":"2021","journal-title":"J. Pharm. Biomed. Anal."},{"issue":"12","key":"10.1016\/j.jchromb.2026.124927_bb0195","doi-asserted-by":"crossref","DOI":"10.1002\/bmc.5212","article-title":"Accelerated stability study of the ester prodrug remdesivir: recently FDA-approved Covid-19 antiviral using reversed-phase-HPLC with fluorimetric and diode array detection","volume":"35","author":"Hamdy","year":"2021","journal-title":"Biomed. Chromatogr."},{"key":"10.1016\/j.jchromb.2026.124927_bb0200","first-page":"1273","article-title":"An Rp-Hplc method for the quantitative determination of remdesivir in intravenous dosage form","author":"Thummar","year":"2023","journal-title":"Int. J. Pharm. Sci. Res."},{"issue":"48","key":"10.1016\/j.jchromb.2026.124927_bb0205","doi-asserted-by":"crossref","first-page":"6666","DOI":"10.1039\/D3AY01562A","article-title":"A validated eco-friendly HPLC-FLD for analysis of the first approved antiviral remdesivir with other potential add-on therapies for COVID-19 in human plasma and pharmaceuticals","volume":"15","author":"Taha","year":"2023","journal-title":"Anal. Methods"},{"issue":"8","key":"10.1016\/j.jchromb.2026.124927_bb0210","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1089\/adt.2021.074","article-title":"Development and validation of high-performance liquid chromatography method for the quantification of remdesivir in intravenous dosage form","volume":"19","author":"Jitta","year":"2021","journal-title":"Assay Drug Dev. Technol."},{"issue":"8","key":"10.1016\/j.jchromb.2026.124927_bb0215","doi-asserted-by":"crossref","first-page":"662","DOI":"10.2174\/0115734129263384230928052923","article-title":"Development of simple HPLC-UV method for the simultaneous determination of repaglinide, dexamethasone, and remdesivir, and its application to synthetic mixture and human plasma","volume":"19","author":"Smerikarova","year":"2023","journal-title":"Curr. Pharm. Anal."},{"issue":"4","key":"10.1016\/j.jchromb.2026.124927_bb0220","doi-asserted-by":"crossref","DOI":"10.31788\/RJC.2021.1446373","article-title":"Development and validation of a new HPLC bioanalytical internal standard method for the analysis of remdesivirin human plasma","volume":"14","author":"Kishore","year":"2021","journal-title":"Rasayan J. Chem."},{"issue":"1","key":"10.1016\/j.jchromb.2026.124927_bb0225","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1515\/revac-2021-0141","article-title":"Rapid sensitive bioscreening of remdesivir in COVID-19 medication: selective drug determination in the presence of six co-administered therapeutics","volume":"40","author":"Abdel Moneim","year":"2021","journal-title":"Rev. Anal. Chem."},{"issue":"12","key":"10.1016\/j.jchromb.2026.124927_bb0230","doi-asserted-by":"crossref","first-page":"1354","DOI":"10.1002\/jcph.354","article-title":"The pharmacokinetics, pharmacodynamics, and safety of baricitinib, an oral JAK 1\/2 inhibitor, in healthy volunteers","volume":"54","author":"Shi","year":"2014","journal-title":"J. Clin. Pharmacol."},{"issue":"8","key":"10.1016\/j.jchromb.2026.124927_bb0235","doi-asserted-by":"crossref","first-page":"952","DOI":"10.1002\/cpdd.868","article-title":"Pharmacokinetics, safety, and tolerability of single-and multiple-dose once-daily baricitinib in healthy Chinese subjects: a randomized placebo-controlled study","volume":"9","author":"Zhao","year":"2020","journal-title":"Clin. Pharmacol. Drug Dev."},{"issue":"7","key":"10.1016\/j.jchromb.2026.124927_bb0240","doi-asserted-by":"crossref","first-page":"655","DOI":"10.3390\/ph14070655","article-title":"ADME and pharmacokinetic properties of remdesivir: its drug interaction potential","volume":"14","author":"Deb","year":"2021","journal-title":"Pharmaceuticals"},{"issue":"7","key":"10.1016\/j.jchromb.2026.124927_bb0245","doi-asserted-by":"crossref","first-page":"1195","DOI":"10.1038\/s41401-020-00537-9","article-title":"Pharmacokinetics and tissue distribution of remdesivir and its metabolites nucleotide monophosphate, nucleotide triphosphate, and nucleoside in mice","volume":"42","author":"Hu","year":"2021","journal-title":"Acta Pharmacol. Sin."},{"issue":"19","key":"10.1016\/j.jchromb.2026.124927_bb0250","doi-asserted-by":"crossref","first-page":"7598","DOI":"10.1039\/D3GC02347H","article-title":"Blue applicability grade index (BAGI) and software: a new tool for the evaluation of method practicality","volume":"25","author":"Manousi","year":"2023","journal-title":"Green Chem."},{"issue":"14","key":"10.1016\/j.jchromb.2026.124927_bb0255","doi-asserted-by":"crossref","first-page":"10076","DOI":"10.1021\/acs.analchem.0c01887","article-title":"AGREE - analytical GREEnness metric approach and software","volume":"92","author":"Pena-Pereira","year":"2020","journal-title":"Anal. Chem."},{"issue":"3","key":"10.1016\/j.jchromb.2026.124927_bb0260","doi-asserted-by":"crossref","DOI":"10.1039\/D0AY02169E","article-title":"Comparative study of four greenness assessment tools for selection of greenest analytical method for assay of hyoscine: N -butyl bromide","volume":"13","author":"Gamal","year":"2021","journal-title":"Anal. Methods"},{"issue":"October","key":"10.1016\/j.jchromb.2026.124927_bb0265","first-page":"2022","article-title":"Green analytical chemistry metrics: a review","volume":"238","author":"Sajid","year":"2021","journal-title":"Talanta"},{"key":"10.1016\/j.jchromb.2026.124927_bb0270","doi-asserted-by":"crossref","DOI":"10.1016\/j.microc.2023.109511","article-title":"Development of a simple, eco-friendly HPLC-DAD method for tulathromycin analysis: ensuring stability and assessing greenness","volume":"195","author":"Algethami","year":"2023","journal-title":"Microchem. J."}],"container-title":["Journal of Chromatography B"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1570023226000164?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1570023226000164?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,12]],"date-time":"2026-09-12T16:16:27Z","timestamp":1789229787000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1570023226000164"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3]]},"references-count":54,"alternative-id":["S1570023226000164"],"URL":"https:\/\/doi.org\/10.1016\/j.jchromb.2026.124927","relation":{},"ISSN":["1570-0232"],"issn-type":[{"value":"1570-0232","type":"print"}],"subject":[],"published":{"date-parts":[[2026,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"High-sensitivity dual analysis of Baricitinib and remdesivir in serum and urine using HPLC-fluorescence and LC-MS approaches in COVID-19 therapy","name":"articletitle","label":"Article Title"},{"value":"Journal of Chromatography B","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jchromb.2026.124927","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"124927"}}